Metagenomi Therapeutics, Inc. Revenue
Metagenomi Therapeutics, Inc. (MGX) reported Revenue of $1.25 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-05-11
- Metagenomi Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.25M, a 69.76% decline year-over-year.
- Metagenomi Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $3.91M, a 59.32% decline year-over-year.
- Metagenomi Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $8.66M, a 24.80% decline year-over-year.
- Metagenomi Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $8.51M, a 57.45% decline year-over-year.
- Metagenomi Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $25.21M, a 51.79% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $52.30M, a 16.84% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $44.76M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.25M 10-Q · filed 2026-05-11 | $5.16M derived: sum of 2 quarters · filed 2026-05-11 | $13.82M derived: sum of 3 quarters · filed 2026-05-11 | $22.33M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $12.57M derived: sum of 2 quarters · filed 2026-03-05 | $21.08M derived: sum of 3 quarters · filed 2026-03-05 | $25.21M 10-K · filed 2026-03-05 |
| 2025-09-30 | $8.66M 10-Q · filed 2025-11-12 | $17.17M derived: sum of 2 quarters · filed 2025-11-12 | $21.30M 10-Q · filed 2025-11-12 | $30.91M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-06-30 | $8.51M 10-Q · filed 2025-08-12 | $12.64M 10-Q · filed 2025-08-12 | $22.25M derived: sum of 3 quarters · filed 2026-05-11 | $33.77M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-03-31 | $4.13M 10-Q · filed 2026-05-11 | $13.74M derived: sum of 2 quarters · filed 2026-05-11 | $25.25M derived: sum of 3 quarters · filed 2026-05-11 | $45.26M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $9.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $21.13M derived: sum of 2 quarters · filed 2026-03-05 | $41.14M derived: sum of 3 quarters · filed 2026-03-05 | $52.30M 10-K · filed 2026-03-05 |
| 2024-09-30 | $11.51M 10-Q · filed 2025-11-12 | $31.52M derived: sum of 2 quarters · filed 2025-11-12 | $42.68M 10-Q · filed 2025-11-12 | $55.08M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $20.01M 10-Q · filed 2025-08-12 | $31.17M 10-Q · filed 2025-08-12 | $43.57M derived: sum of 3 quarters · filed 2025-08-12 | $55.93M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $11.16M 10-Q · filed 2025-05-13 | $23.56M derived: sum of 2 quarters · filed 2025-05-13 | $35.92M derived: sum of 3 quarters · filed 2025-05-13 | $47.26M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $24.76M derived: sum of 2 quarters · filed 2025-03-17 | $36.10M derived: sum of 3 quarters · filed 2025-03-17 | $44.76M 10-K · filed 2025-03-17 |
| 2023-09-30 | $12.36M 10-Q · filed 2024-11-13 | $23.70M derived: sum of 2 quarters · filed 2024-11-13 | $32.36M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $11.34M 10-Q · filed 2024-08-14 | $19.99M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $8.66M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |